Clinical Trials on Respiratory Syncytial Virus in United States

Total 26136 results

Sanofi Pasteur, a Sanofi Company

Recruiting

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (BEAR)

Respiratory Syncytial Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Respiratory Syncytial Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

Respiratory Syncytial Virus Infection | Antiviral Prophylaxis

United States
MedImmune LLC

Completed

MEDI-557 Adult Dosing (CD-1092)

Respiratory Syncytial Virus

United States
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Respiratory Syncytial Virus Infection

United States, Puerto Rico
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Respiratory Syncytial Virus (RSV)

United States
University of Rochester

Active, not recruiting

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

Infections, Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Prevention of RSV Infections in Bone Marrow Transplant Recipients

Respiratory Syncytial Virus Infection

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
Quidel Corporation

Completed

Sofia RSV FIA Field Study

Respiratory Syncytial Virus

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Respiratory Syncytial Virus (RSV)

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
Novavax

Completed

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Respiratory Syncytial Virus (RSV)

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (VAD00001)

Respiratory Syncytial Virus Infection

Honduras, United States, Chile
University of Wisconsin, Madison

Completed

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children (IIRI)

Respiratory Syncytial Virus Infection

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

Respiratory Syncytial Virus Infection Prevention

Germany, Spain, Belgium, Sweden, United States
University of Oxford
Innovative Medicines Initiative; Respiratory syncytial virus consortium in...

Active, not recruiting

Understanding RSV: Severe Disease and the Long Term Consequences

Respiratory Syncytial Virus (RSV)

United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
ModernaTX, Inc.

Active, not recruiting

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Respiratory Syncytial Virus

United States
Pfizer

Completed

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (MONET)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
Merck Sharp & Dohme LLC

Completed

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Respiratory Syncytial Virus

United Kingdom
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP 938 Regimens in Children With RSV (RSVPEDs)

Respiratory Syncytial Virus (RSV)

United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
ModernaTX, Inc.

Recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus

Canada, United Kingdom, Japan, United States, Chile, Denmark, Panama, South Africa
Novavax

Completed

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Respiratory Syncytial Virus (RSV)

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Respiratory Syncytial Virus

United States, Panama
Merck Sharp & Dohme LLC

Completed

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

Respiratory Syncytial Viruses

United Kingdom
ModernaTX, Inc.

Recruiting

A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults

Respiratory Syncytial Virus

Canada, United States, United Kingdom, Puerto Rico
Gilead Sciences

Completed

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infection

Korea, Republic of, Australia, Israel, New Zealand, Netherlands, United States, France, United Kingdom, Italy, Belgium, Poland
Pfizer

Completed

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Respiratory Syncytial Virus (RSV)

United Kingdom
ModernaTX, Inc.

Active, not recruiting

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Respiratory Syncytial Virus | Human Metapneumovirus

Spain, United Kingdom, Canada, Australia, United States, South Africa, Poland, Colombia, Argentina, Latvia, Panama
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
MedImmune LLC

Terminated

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

Respiratory Syncytial Virus

United States, Chile, South Africa, Canada, Estonia, Lithuania, Latvia
ModernaTX, Inc.

Active, not recruiting

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Respiratory Syncytial Virus

United States
Gilead Sciences

Completed

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus (RSV)

United States, Belgium, Canada, Netherlands, Australia, Germany, United Kingdom, France
University of Alabama at Birmingham

Completed

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

Respiratory Syncytial Virus

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus Infection

Australia, United States
Pfizer

Completed

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Alnylam Pharmaceuticals

Completed

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States

3

Subscribe